Search research articles
Contact Us
Filters
Showing results (361-370 of 373) with videos related to
Page
of 38
Sort By:
Journal of Gastroenterology and Hepatology
|
March 23, 2016
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin
Lai Wei, Mingxiang Zhang, Min Xu, et al.
World Journal of Gastroenterology
|
March 30, 2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
Ira Jacobson, Stefan Zeuzem, Robert Flisiak, et al.
Annals of Hepatology
|
October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection
Maribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
February 18, 2020
[Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China]
W Chen, Q Wang, Y Q Li, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
The Lancet. Infectious Diseases
|
June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]
|
November 26, 2025
[Long-term survival outcomes and prognostic factors following radical resection of pancreatic body and tail cancer:a retrospective analysis of 992 patients]
D Xu, Y Wu, K Zhang, et al.
The New England Journal of Medicine
|
July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
JAMA
|
May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
Fred Poordad, William Sievert, Lindsay Mollison, et al.
The Journal of Physical Chemistry. B
|
June 4, 2014
All-atom empirical potential for molecular modeling and dynamics studies of proteins
A D MacKerell, D Bashford, M Bellott, et al.
Page
of 38
Search research articles
Search
Showing results (361-370 of 373) with videos related to
Sort By:
Page
of 38
Journal of Gastroenterology and Hepatology
|
March 23, 2016
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin
Lai Wei, Mingxiang Zhang, Min Xu, et al.
World Journal of Gastroenterology
|
March 30, 2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
Ira Jacobson, Stefan Zeuzem, Robert Flisiak, et al.
Annals of Hepatology
|
October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection
Maribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
February 18, 2020
[Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China]
W Chen, Q Wang, Y Q Li, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
The Lancet. Infectious Diseases
|
June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]
|
November 26, 2025
[Long-term survival outcomes and prognostic factors following radical resection of pancreatic body and tail cancer:a retrospective analysis of 992 patients]
D Xu, Y Wu, K Zhang, et al.
The New England Journal of Medicine
|
July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
JAMA
|
May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
Fred Poordad, William Sievert, Lindsay Mollison, et al.
The Journal of Physical Chemistry. B
|
June 4, 2014
All-atom empirical potential for molecular modeling and dynamics studies of proteins
A D MacKerell, D Bashford, M Bellott, et al.
Page
of 38